E-resources
Peer reviewed
Open access
-
Williams, Sophie T.; Chatzikyriakou, Prodromos; Carroll, Paul V.; McGowan, Barbara M.; Velusamy, Anand; White, Gemma; Obholzer, Rupert; Akker, Scott; Tufton, Nicola; Casey, Ruth T.; Maher, Eamonn R.; Park, Soo‐Mi; Porteous, Mary; Dyer, Rebecca; Tan, Tricia; Wernig, Florian; Brady, Angela F.; Kosicka‐Slawinska, Monika; Whitelaw, Benjamin C.; Dorkins, Huw; Lalloo, Fiona; Brennan, Paul; Carlow, Joseph; Martin, Richard; Mitchell, Anna L.; Harrison, Rachel; Hawkes, Lara; Newell‐Price, John; Kelsall, Alan; Igbokwe, Rebecca; Adlard, Julian; Schirwani, Schaida; Davidson, Rosemarie; Morrison, Patrick J.; Chung, Teng‐Teng; Bowles, Christopher; Izatt, Louise
Clinical endocrinology, April 2022, 2022-04-00, 20220401, Volume: 96, Issue: 4Journal Article
Objective Phaeochromocytomas and paragangliomas (PPGL) are rare, but strongly heritable tumours. Variants in succinate dehydrogenase (SDH) subunits are identified in approximately 25% of cases. However, clinical and genetic information of patients with SDHC variants are underreported. Design This retrospective case series collated data from 18 UK Genetics and Endocrinology departments. Patients Both asymptomatic and disease‐affected patients with confirmed SDHC germline variants are included. Measurements Clinical data including tumour type and location, surveillance outcomes and interventions, SDHC genetic variant assessment, interpretation, and tumour risk calculation. Results We report 91 SDHC cases, 46 probands and 45 non‐probands. Fifty‐one cases were disease‐affected. Median age at genetic diagnosis was 43 years (range: 11–79). Twenty‐four SDHC germline variants were identified including six novel variants. Head and neck paraganglioma (HNPGL, n = 30, 65.2%), extra‐adrenal paraganglioma (EAPGL, n = 13, 28.2%) and phaeochromocytomas (PCC) (n = 3, 6.5%) were present. One case had multiple PPGLs. Malignant disease was reported in 19.6% (9/46). Eight cases had non‐PPGL SDHC‐associated tumours, six gastrointestinal stromal tumours (GIST) and two renal cell cancers (RCC). Cumulative tumour risk (95% CI) at age 60 years was 0.94 (CI: 0.79–0.99) in probands, and 0.16 (CI: 0–0.31) in non‐probands, respectively. Conclusions This study describes the largest cohort of 91 SDHC patients worldwide. We confirm disease‐affected SDHC variant cases develop isolated HNPGL disease in nearly 2/3 of patients, EAPGL and PCC in 1/3, with an increased risk of GIST and RCC. One fifth developed malignant disease, requiring comprehensive lifelong tumour screening and surveillance.
Author
Shelf entry
Permalink
- URL:
Impact factor
Access to the JCR database is permitted only to users from Slovenia. Your current IP address is not on the list of IP addresses with access permission, and authentication with the relevant AAI accout is required.
Year | Impact factor | Edition | Category | Classification | ||||
---|---|---|---|---|---|---|---|---|
JCR | SNIP | JCR | SNIP | JCR | SNIP | JCR | SNIP |
Select the library membership card:
If the library membership card is not in the list,
add a new one.
DRS, in which the journal is indexed
Database name | Field | Year |
---|
Links to authors' personal bibliographies | Links to information on researchers in the SICRIS system |
---|
Source: Personal bibliographies
and: SICRIS
The material is available in full text. If you wish to order the material anyway, click the Continue button.